Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance

Br J Psychiatry. 2009 Apr;194(4):342-9. doi: 10.1192/bjp.bp.108.050278.

Abstract

Background: People with severe depressive illness have raised levels of cortisol and reduced glucocorticoid receptor function.

Aims: To obtain a physiological assessment of hypothalamic-pituitary-adrenal (HPA) axis feedback status in an in-patient sample with depression and to relate this to prospectively determined severe treatment resistance.

Method: The prednisolone suppression test was administered to 45 in-patients with depression assessed as resistant to two or more antidepressants and to 46 controls, prior to intensive multimodal in-patient treatment.

Results: The patient group had higher cortisol levels than controls, although the percentage suppression of cortisol output after prednisolone in comparison with placebo did not differ. Non-response to in-patient treatment was predicted by a more dysfunctional HPA axis (higher cortisol levels post-prednisolone and lower percentage suppression).

Conclusions: In patients with severe depression, HPA axis activity is reset at a higher level, although feedback remains intact. However, prospectively determined severe treatment resistance is associated with an impaired feedback response to combined glucocorticoid and mineralocorticoid receptor activation by prednisolone.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antidepressive Agents / therapeutic use
  • Case-Control Studies
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / physiopathology
  • Drug Resistance / drug effects
  • England
  • Female
  • Glucocorticoids*
  • Humans
  • Hydrocortisone / metabolism
  • Hypothalamo-Hypophyseal System / drug effects*
  • Hypothalamo-Hypophyseal System / physiopathology
  • Male
  • Pituitary-Adrenal System / drug effects*
  • Pituitary-Adrenal System / physiopathology
  • Prednisolone*
  • Prospective Studies
  • Receptors, Glucocorticoid / metabolism
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Glucocorticoids
  • Receptors, Glucocorticoid
  • Prednisolone
  • Hydrocortisone